Sonnet BioTherapeutics Holdings, Inc. financial data

Location
Princeton, NJ
Fiscal year end
30 September
Latest financial report
10-Q - Q2 2025 - 13 Aug 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 92% % -34.5%
Debt-to-equity 1,258% % 598%
Return On Assets -342% % -140.78%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6,754,352 shares 30%
Common Stock, Shares, Outstanding 3,332,728 shares -36.14%
Entity Public Float $46,150,766 USD 532%
Common Stock, Value, Issued $333 USD -36.21%
Weighted Average Number of Shares Outstanding, Basic 3,965,220 shares 530%
Weighted Average Number of Shares Outstanding, Diluted 3,965,220 shares 530%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $1,000,000 USD 5,269%
Research and Development Expense $7,395,423 USD 16%
General and Administrative Expense $7,663,249 USD 29%
Operating Income (Loss) $-14,058,672 USD -14.52%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $-3,775,804 USD -7.71%
Income Tax Expense (Benefit) $158,400 USD
Net Income (Loss) Attributable to Parent $-13,556,225 USD -69.76%
Earnings Per Share, Basic -7 USD/shares 94%
Earnings Per Share, Diluted -7 USD/shares 94%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $149,456 USD -93.43%
Accounts Receivable, after Allowance for Credit Loss, Current $500,000 USD
Assets, Current $1,319,572 USD -74.27%
Property, Plant and Equipment, Net $12,854 USD -45.84%
Operating Lease, Right-of-Use Asset $64,640 USD -54.42%
Other Assets, Noncurrent $486,381 USD -0.43%
Assets $2,055,347 USD -64.54%
Accounts Payable, Current $3,750,083 USD 100%
Accrued Liabilities, Current $3,315,404 USD 3.5%
Liabilities, Current $5,101,826 USD 64%
Operating Lease, Liability, Noncurrent $23,634 USD -78.7%
Liabilities $5,101,826 USD 61%
Retained Earnings (Accumulated Deficit) $-128,108,617 USD -11.83%
Stockholders' Equity Attributable to Parent $-3,046,479 USD -216.36%
Liabilities and Equity $2,055,347 USD -64.54%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $-2,910,246 USD 5.9%
Net Cash Provided by (Used in) Financing Activities $7,622,293 USD 99%
Common Stock, Shares Authorized 125,000,000 shares 0%
Common Stock, Shares, Issued 3,332,728 shares -36.14%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $4,712,047 USD 531%
Deferred Tax Assets, Valuation Allowance $36,480,967 USD -1.67%
Deferred Tax Assets, Gross $36,520,442 USD -1.73%
Operating Lease, Liability $130,864 USD -35.82%
Depreciation $3,211 USD 0%
Lessee, Operating Lease, Liability, to be Paid $143,703 USD -39.45%
Operating Lease, Liability, Current $68,837 USD -15.38%
Lessee, Operating Lease, Liability, to be Paid, Year Two $48,216 USD -49.5%
Lessee, Operating Lease, Liability, to be Paid, Year One $95,487 USD 2%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $12,839 USD -61.57%
Lessee, Operating Lease, Liability, to be Paid, Year Three $48,216 USD -49.5%
Deferred Tax Assets, Operating Loss Carryforwards $26,754,767 USD -4.44%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares
Additional Paid in Capital $125,061,805 USD 6.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $39,475 USD -36.74%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares